Urocortin has been shown to interact with Corticotropin releasing hormone receptor 1.

CP-154,526 is a potent and selective antagonist of the corticotropin releasing hormone receptor 1 developed by Pfizer.

These cells respond to corticotropin releasing hormone (CRH) and make up about 20% of the cells in the anterior pituitary.

Stimulation of the hypothalamic-pituitary-adrenal axis by stimulating the release of corticotropin releasing hormone (CRH)

Rosenfeld and his colleagues reported that the corticotropin releasing hormone promoter is transcriptionally up-regulated by brain-2 (N-Oct 3)[32].

Stress hormones in mice such as serum corticotropin releasing factor, adrenal corticotropin releasing hormone, and corticosterone were reduced after psoralidin administration.

Gene by Environment interaction and resilience: Effects of child maltreatment and serotonin, corticotropin releasing hormone, dopamine, and oxytocin genes.

The adrenal cortex responds by signaling the release of the corticosteroids cortisol and corticotropin releasing hormone (CRH) directly into the bloodstream.

Administration of corticotropin releasing hormone (CRH) can differentiate this condition from ectopic ACTH secretion.

ACTH is in turn controlled by the hypothalamic peptide corticotropin releasing hormone (CRH), which is under nervous control.

Corticotropin releasing hormone receptor 1 (CRHR1, also known as CRF-R, CRF1)

Interactive effects of corticotropin releasing hormone receptor 1, serotonin transporter linked polymorphic region, and child maltreatment on diurnal cortisol regulation and internalizing symptomatology.

This interaction takes place as Arginine Vasopressin works with corticotropin releasing hormone to stimulate the pituitary gland to secrete ACTH.

This is most often as a result of a pituitary adenoma or due to excess production of hypothalamus CRH (Corticotropin releasing hormone) (tertiary hypercortisolism/hypercorticism).

Astressin-B (AST) is a nonselective corticotropin releasing hormone antagonist that reduces the synthesis of ACTH and cortisol.

Corticotropin releasing factor (CRF), also known as Corticotropin releasing hormone, is an endogenous peptide hormone which is released in response to various triggers such as chronic stress.

Normally, the hypothalamus in the brain produces corticotropin releasing hormone, or CRH, which stimulates the pituitary gland in the brain to produce adrenocorticotropin hormone, or ACTH.

In the human body, the steps that lead to the release of glucocorticoids such as cortisol begin with the release of corticotropin releasing hormone (CRH) and arginine vasopressin (AVP).

Corticotropin releasing hormone receptor 2 (CRHR2) is a human protein, also known as CRF, with CRF now being the IUPHAR-recommended name.

Stimulation of 5-HT receptors leads to increase of corticotropin releasing hormone (CRH) and vasopressin mRNA in the paraventricular nucleus and proopiomelanocortin in the anterior pituitary lobe.

Activation of Y is thought to be involved in functions such as regulation of appetite and anxiety, and BIBP-3226 has anxiogenic and anorectic effects, as well as blocking the Y-mediated corticotropin releasing hormone release.

A Corticotropin releasing hormone antagonist is a specific type of receptor antagonist which blocks the receptor sites for Corticotropin releasing hormone (also known as Corticotropin releasing factor (CRF)), blocking therefore the consequent secretions of ACTH and cortisol.